2269.HK

WuXi Biologics (Cayman) Inc. [2269.HK] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

2269.HK Stock Summary

Top 10 Correlated ETFs

2269.HK

Top 10 Correlated Stocks

2269.HK

In the News

2269.HK Financial details

Company Rating
-
Market Cap
59.2B
Income
4.15B
Revenue
16.55B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
12.74K
Optionable
No
Shortable
Yes
Earnings
22 Mar 2024
P/E
52.24
Forward P/E
-
PEG
32.55
P/S
12.13
P/B
2.98
P/C
-
P/FCF
108.63
Quick Ratio
1.07
Current Ratio
2.2
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.94
EPS next Y
-
EPS next Q
-
EPS this Y
30.86%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
45.96%
Revenue last 5Y
43.21%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-5.26%
SMA50
9.09%
SMA100
-7.69%
Inst Own
-
Inst Trans
-
ROA
4%
ROE
8%
ROC
0.06%
Gross Margin
41%
Oper. Margin
31%
Profit Margin
24%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
12.9-56.7
52W High
-37.29%
52W Low
+192.67%
RSI
43
Rel Volume
0.29
Avg Volume
68.52M
Volume
19.53M
Perf Week
-5.08%
Perf Month
-8.11%
Perf Quarter
-3.73%
Perf Half Y
-9.9%
-
-
-
-
Beta
0.623
-
-
Volatility
0.54%, 2.05%
Prev Close
-2.71%
Price
35.12
Change
-5.34%

Something similar

Top by Market Cap
BRYN.DE
APC.DE
META
0YXG.L
ABEA.DE
Top Correlated ETFs
2845.HK
2806.HK
Top Correlated Stocks
2359.HK
3800.HK
1801.HK
2285.HK
0069.HK
Similar Market Cap
ADS.DE
145210.KS
034590.KS
7250.T
BPE.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 68.52M
  • Market Capitalization 59.2B
  • Employee 12.74K
  • CEO Dr. Zhisheng Chen
  • Headquarters Wuxi,CN
  • IPO Date 2017-06-13
  • Website https://www.wuxibiologics.com

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.